Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sight Sciences, Inc.

4.69
+1.2435.94%
Post-market: 4.55-0.1400-2.99%19:59 EDT
Volume:1.64M
Turnover:7.32M
Market Cap:245.60M
PE:-4.89
High:4.80
Open:3.90
Low:3.89
Close:3.45
52wk High:6.08
52wk Low:2.03
Shares:52.37M
Float Shares:28.82M
Volume Ratio:22.13
T/O Rate:5.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9597
EPS(LYR):-1.0274
ROE:-57.10%
ROA:-22.40%
PB:3.51
PE(LYR):-4.56

Loading ...

Sight Sciences Q2 revenue falls 8% but beats estimates

Reuters
·
Aug 08

Sight Sciences Q2 EPS $(0.23) Beats $(0.29) Estimate, Sales $19.564M Beat $18.183M Estimate

Benzinga
·
Aug 08

Sight Sciences Inc - Raises 2025 Revenue Guidance to $72-$76 Mln

THOMSON REUTERS
·
Aug 08

Sight Sciences : Exposed to Tariffs Imposed by U.S. on China Because Most Products Are Produced and Assembled in China

THOMSON REUTERS
·
Aug 08

Sight Sciences Inc: Reiterates Adjusted Operating Expenses Guidance for Full Year 2025

THOMSON REUTERS
·
Aug 08

Sight Sciences: Tariff Exposure Would Increase Cost of Surgical Glaucoma Segment's Goods by $1.0 Mln -$1.5 Mln for FY

THOMSON REUTERS
·
Aug 08

Sight Sciences Q2 EPS USD -0.23

THOMSON REUTERS
·
Aug 08

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

GlobeNewswire
·
Aug 08

Sight Sciences Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
Aug 06

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

GlobeNewswire
·
Jul 30

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

GlobeNewswire
·
Jul 29

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

GlobeNewswire
·
Jul 25

Sight Sciences Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Jul 15

Paul Badawi, President and CEO, Reports Disposal of Common Shares of Sight Sciences Inc

Reuters
·
Jul 08

CFO Alison Bauerlein Reports Disposal of Common Shares in Sight Sciences Inc

Reuters
·
Jul 08

Matthew Link, Chief Commercial Officer, Reports Disposal of Common Shares in Sight Sciences Inc

Reuters
·
Jul 08

Sight Sciences Is Maintained at Neutral by Piper Sandler

Dow Jones
·
Jun 18

Sight Sciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 06

Director and 10% Owner Staffan Encrantz Reports Acquisition of Common Shares in Sight Sciences Inc

Reuters
·
Jun 04

Director and 10% Owner Staffan Encrantz Reports Acquisition of Sight Sciences Common Shares

Reuters
·
May 30